GlassScriptPhysician profile
Ellen O Turner
NPI 1396795886
$56,783.42
in general payments reported to CMS, 2019-2025
34 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,919 · 2020: $1,749 · 2021: $3,838 · 2022: $15K · 2023: $18K · 2024: $2,392 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $8,927 · Consulting Fee: $8,875 · Travel and Lodging: $2,240 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,000.00 |
| Food and Beverage | $8,927.24 |
| Consulting Fee | $8,875.00 |
| Travel and Lodging | $2,239.56 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21,172.95 | 2019-2025 | Botox, Kybella, Rinvoq |
| Allergan, INC. | $14,150.44 | 2019-2022 | |
| Merz North America, INC. | $12,593.73 | 2020-2025 | |
| Galderma Laboratories, L.P. | $2,702.52 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Genzyme Corporation | $975.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $638.71 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $608.33 | 2019-2025 | |
| Leo Pharma INC. | $529.98 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $401.61 | 2019-2023 | Remicade, Stelara, Simponi Aria |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $340.72 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Ucb, INC. | $316.60 | 2020-2025 | Bimzelx, Cimzia |
| Vyne Pharmaceuticals INC. | $300.28 | 2020-2021 | |
| Botanix Sb INC | $270.14 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $269.18 | 2022-2025 | Sotyktu |
| Incyte Corporation | $242.62 | 2024-2025 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $184.63 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $176.91 | 2023-2024 | Zoryve |
| Celgene Corporation | $137.76 | 2019 | |
| Sun Pharmaceutical Industries INC. | $132.76 | 2019-2024 | |
| Journey Medical Corporation | $128.25 | 2023-2025 | |
| Pfizer INC. | $122.28 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $95.13 | 2019-2023 | |
| Lilly USA, LLC | $50.38 | 2019-2025 | Ebglyss, Taltz |
| Dermavant Sciences, INC. | $42.63 | 2023-2024 | Vtama |
| Almirall LLC | $27.54 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.20 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $23.44 | 2019 | |
| Mayne Pharma Commercial LLC | $22.03 | 2023 | |
| Melinta Therapeutics, LLC | $21.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.30 | 2021 | |
| Aclaris Therapeutics, INC. | $18.44 | 2019 | |
| Biofrontera INC. | $16.25 | 2025 | Ameluz |
| Verrica Pharmaceuticals INC. | $16.16 | 2023 | Ycanth |
| Sensus Healthcare, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.